USANA Health Sciences, Inc. USNA
14.50
0.24
1.68%
as of 25 Sep
- Market cap
- $263.5M
- P/E
- 0.0×
Follow USNA
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
| P/E ratio |
+8 more quarters Free account |
31.31 | 35.69 | 37.17 | 0.00 |
| P/S ratio | 0.55 | 0.39 | 0.35 | 0.43 | |
| P/FCF ratio | 26.96 | 29.27 | 46.49 | 19.83 | |
| P/Operating CF | (257.00) | (107.33) | 32.94 | 16.93 | |
| P/B ratio | 0.95 | 0.68 | 0.59 | 0.75 | |
| Price to Tangible BV | 2.05 | 1.39 | 1.16 | 1.35 | |
| EV/Sales | 0.40 | 0.23 | 0.18 | 0.26 | |
| EV/EBITDA | 4.74 | 2.75 | 2.21 | 3.48 | |
| EV/Operating CF | 11.59 | 9.50 | 9.96 | 8.40 | |
| EV/FCF | 19.55 | 17.08 | 23.94 | 11.71 | |
| Quick Ratio | 1.22 | 1.27 | 1.47 | 1.63 | |
| Current Ratio | 2.23 | 2.24 | 2.51 | 2.66 | |
| Net Debt/EBITDA | (13.47) | (11.23) | (6.88) | (9.21) | |
| Debt/Assets | 0.00% | 0.00% | 0.00% | 0.00% | |
| Debt/Equity | 0.00 | 0.00 | 0.00 | 0.00 | |
| Asset Turnover | 1.31 | 1.24 | 1.25 | 1.27 | |
| Operating CF/Net income | 0.30 | 1.91 | 1.30 | (1.09) | |
| Capex/Depreciation | (0.33) | 0.11 | (0.27) | (0.08) | |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 | |
| Research and Development Expense of Revenue | 0.00% | 0.00% | 0.00% | 0.00% | |
| Selling, General and Administrative Expense of Revenue | 76.58% | 73.39% | 70.70% | 74.26% | |
| Intangible Assets out of Total Assets | 0.39 | 0.36 | 0.36 | 0.33 | |
| Share Based Compensation of Revenue | 1.67% | 1.66% | 1.38% | 1.52% | |
| Graham Net Nets | 0.13 | 0.22 | 0.31 | 0.26 | |
| Graham Number | 23.91 | 18.87 | 17.68 | 0.00 | |
| Earnings Yield | 3.19% | 2.80% | 2.69% | (5.67%) | |
| Free Cash Flow Yield | 3.71% | 3.42% | 2.15% | 5.04% | |
| Revenue per Share | 11.68 | 12.20 | 13.60 | 12.08 | |
| Operating CF per Share | (0.11) | (0.18) | 0.53 | 1.26 | |
| Capex per Share | (0.17) | 0.06 | (0.14) | (0.17) | |
| Free Cash Flow per Share | (0.28) | (0.12) | 0.39 | 1.09 | |
| Cash per Share | 7.95 | 8.54 | 8.85 | 9.12 | |
| Shareholders Equity per Share | 28.87 | 28.76 | 29.54 | 28.47 | |
| Interest Debt per Share | 0.00 | 0.00 | 0.00 | 0.00 | |
| Book value per Share | 28.87 | 28.76 | 29.54 | 28.47 | |
| Free Cash Flow | (5.16) | (2.28) | 7.16 | 20.18 | |
| Working Capital | 145.40 | 159.84 | 176.99 | 175.39 | |
| Capital Expenditures | (3.20) | 1.11 | (2.60) | (3.14) | |
| Net Current Asset Value | 65.55 | 78.59 | 98.82 | 104.16 | |
| EV/EBIT | 8.74 | 5.67 | 4.65 | 0.00 | |
| Capex to Sales | 0.02 | 0.00 | 0.01 | 0.01 | |
| Net Profit Margin | (3.05%) | (0.78%) | 3.00% | (9.58%) | |
| Price to Operating Income | 12.05 | 9.72 | 9.02 | 0.00 | |
| Other line items | |||||
| Average Receivables | — | 6.52 | 8.54 | 5.25 | |
| Average Payables | 11.63 | 14.62 | 15.10 | 16.67 | |
| Average Inventory | 77.38 | 86.17 | 84.96 | 84.81 | |
| Average Assets | 698.95 | 745.55 | 742.78 | 718.87 | |
| Average Common Equity | 530.58 | 532.61 | 536.66 | 528.68 |
Columns are period end dates